PATENT CLAIM ANALYSIS

Application Number: 16386915
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-09
Patent Classification: ["514", "047000"]

Abstract:
The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

Claim (Index 27):
The method of  claim 1 , wherein the therapeutically effective amount of the composition administered to the subject is increased over time.

Metadata:
- Claim Count in Document: 57.0
- Percentile: 100.0
- Lexical Diversity: 1.63492
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15082207', '15736092', '12205588', '14656096', '15218790']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7434366329361058
- 35 USC 102 Novelty (BERT): 0.7026820084326801
- Combined Prediction Score: 0.7393611704857633
- Mean Citation Score: 405.63436399999983
- Max Citation Score: 810.0359
- Similarity Product: 691.8783531207263

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test